comparemela.com

Latest Breaking News On - Runway into - Page 1 : comparemela.com

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ukraine
United-states
California
Denver
Colorado
Pierre-fabre
Pascal-touchon
Drug-administration
Exchange-commission
Atara-biotherapeutics-inc
International-society-for-cell-gene-therapy
Nasdaq

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results

DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2022 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

China
Australia
Japan
United-states
South-korea
Australian
Paul-papi
Scott-kellen
Company-phase
Drug-administration
Nasdaq
Diamedica-therapeutics-inc

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

China
Australia
Japan
United-states
South-korea
Australian
Exchange-commission
Company-phase
Company-confident-in-plan-to-resolve
Drug-administration
Nasdaq

Revance Provides Corporate Update and Anticipated Milestones for 2021

Press release content from Business Wire. The AP news staff was not involved in its creation. Revance Provides Corporate Update and Anticipated Milestones for 2021 January 7, 2021 GMT NASHVILLE, Tenn. (BUSINESS WIRE) Jan 7, 2021 Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today provided a corporate update, product pipeline timing and anticipated milestones for 2021. Financial Update and Key Launch Metrics: Preliminary Unaudited Full Year 2020 RHA® Collection Revenue of Between $12.5 Million and $13.0 Million. The company expects its first full quarter of unaudited RHA® Collection revenue to be between $9.5 million and $10.0 million for the fourth quarter 2020, bringing full year RHA® Collection revenue to be between $12.5 million and $13.0 million. The company launched the RHA® Collection in September 2020.

California
United-states
Tennessee
Laurence-watts
Jessica-serra
Sara-fahy
Nadine-tosk
Mark-foley
Allergan-inc
Drug-administration
Nasdaq
Injection-in-muscle-movement-disorders

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.